Manufacturer
GLAXOSMITHKLINE AUSTRALIA PTY LTD
Contents
Ondansetron HCl dihydrate
Indication
Postoperative nausea and vomiting, Prophylaxis of chemotherapy-induced nausea and vomiting, Prophylaxis of nausea and vomiting associated with radiation therapy,
Instruction
Administer via slow IV or IM Inj.
Drug interaction
Dexamethasone Na phosphate may potentiate antiemetic effect. May develop serotonin syndrome (including altered mental status, autonomic instability, neuromuscular abnormalities) with SSRIs, MAOIs, mirtazapine, fentanyl, lithium, methylene blue, serotonin noradrenaline reuptake inhibitors (SNRIs). Potent CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampicin) may reduce plasma concentrations and increase clearance of ondansetron. Coadministration with antiarrhythmics (e.g. amiodarone), atenolol, anthracyclines (e.g. doxorubicin, daunorubicin), trastuzumab, erythromycin, and ketoconazole may cause additive prolongation of QT interval and increase risk of arrhythmia. May decrease analgesic effect of tramadol.Potentially Fatal: Concomitant use with apomorphine may result to profound hypotension and loss of consciousness.
Malaysia
